In: Press Release

02 OctGO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment

Cambridge, Mass., Oct. 2, 2018 — GO Therapeutics, Inc. (GO), a company applying new advances in glycoproteomics to develop antibody-based cancer…

Read More

04 OctGO Therapeutics appoints Dr. Robert J. Wills to Board of Directors

Cambridge, MA, October 4, 2017 – GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer…

Read More

25 SepSalubris Pharmaceuticals Invests $5 Million in GO Therapeutics

Strategic investment to help accelerate antibody development programs against novel solid tumor targets Cambridge, MA, September 25, 2017 –GO Therapeutics today…

Read More